This is what I never understood about a safety hold, why couldn't we use the data from CD10 and CD12, The DSMB had already evaluated the safety in both and okayed it.
But with Amarex in the way, why don't we now just use the safety data from Brazil and sidestep Amarex? Also why don't we just unblind from Brazil?